Ness Brent

CEO Ness Brent purchases shares at depressed valuation, but his prior open-market buy posted significant losses in follow-up period.

Ness Brent, Aclarion's CEO, is making his second open-market share purchase in the past six months, buying at prices well below the company's 52-week high. The stock currently trades significantly below that range, and the company remains unprofitable with recent quarterly results showing substantial net losses despite revenue growth. However, Brent's track record on this very trade is cautionary: his previous open-market purchase six months ago was followed by sharp declines in both the near term and longer horizon, suggesting poor timing on his last attempt to buy at attractive prices. Brent is putting capital into a company trading in genuine weakness, but his prior experience buying at what appeared to be depressed valuations has not worked out, and the company's underlying financial deterioration raises questions about whether current prices reflect fair value or something worse. This repeat purchase at lower prices is worth monitoring closely given the disconnect between the CEO's buying conviction and the actual results of his previous identical trade.

CEO Brent Ness purchases 10 shares of ACON at $6.20 amid -99.8% decline from 52-week high and -39.4% revenue drop.

Ness Brent, the Chief Executive Officer, purchased 10 shares at $6.20 on 2025-11-26, increasing holdings from 1 to 11 shares (+1000.0% of prior holdings). The purchase occurs at a stock price of $6.50 (current), which sits -99.8% from the 52-week high of $2699.03—a dramatic valuation collapse. The underlying business context is severe: revenue has contracted by -39.4% annually, the company posted a net loss of $-1.7M on quarterly revenue of $18.9K, and remains unprofitable on a full-year basis. The stock has declined -16.2% over 30 days and -9.1% over 90 days. While a CEO equity purchase by definition signals some level of engagement with shareholder value, the absolute scale is modest (10 shares, $62.00 total) against a company in structural decline, making the transaction difficult to interpret as conviction in a turnaround versus routine compliance or portfolio rebalancing.